Simris Alg AB (publ) (SIMRIS-B) - Total Liabilities

Latest as of March 2026: Skr136.97 Million SEK ≈ $14.74 Million USD

Based on the latest financial reports, Simris Alg AB (publ) (SIMRIS-B) has total liabilities worth Skr136.97 Million SEK (≈ $14.74 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SIMRIS-B net assets growth trend to track the company's year-over-year net asset growth rate.

Simris Alg AB (publ) - Total Liabilities Trend (2012–2025)

This chart illustrates how Simris Alg AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See SIMRIS-B FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Simris Alg AB (publ) Competitors by Total Liabilities

The table below lists competitors of Simris Alg AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
Securemetric Berhad
KLSE:0203
Malaysia RM24.78 Million
Leeuwin Metals Ltd
AU:LM1
Australia AU$2.08 Million
Climeon AB (publ)
ST:CLIME-B
Sweden Skr31.28 Million
SenzaGen AB
ST:SENZA
Sweden Skr24.13 Million
Firefly Neuroscience, Inc.
NASDAQ:AIFF
USA $2.75 Million
Wanted Lab Inc.
KQ:376980
Korea ₩23.06 Billion
EG Corporation
KQ:037370
Korea ₩132.48 Billion
Curis Inc
NASDAQ:CRIS
USA $16.98 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Simris Alg AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SIMRIS-B market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.99 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 24.97 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.96 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Simris Alg AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Simris Alg AB (publ) (2012–2025)

The table below shows the annual total liabilities of Simris Alg AB (publ) from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 Skr148.85 Million
≈ $16.02 Million
-1.69%
2024-12-31 Skr151.42 Million
≈ $16.29 Million
+1.66%
2023-12-31 Skr148.94 Million
≈ $16.03 Million
-8.45%
2022-12-31 Skr162.68 Million
≈ $17.51 Million
+1381.58%
2021-12-31 Skr10.98 Million
≈ $1.18 Million
+13.88%
2020-12-31 Skr9.64 Million
≈ $1.04 Million
-43.98%
2019-12-31 Skr17.21 Million
≈ $1.85 Million
+71.18%
2018-12-31 Skr10.05 Million
≈ $1.08 Million
-14.11%
2017-12-31 Skr11.71 Million
≈ $1.26 Million
+6.13%
2016-12-31 Skr11.03 Million
≈ $1.19 Million
-34.90%
2015-12-31 Skr16.94 Million
≈ $1.82 Million
+1461.47%
2014-12-31 Skr1.08 Million
≈ $116.76K
+54.44%
2013-12-31 Skr702.52K
≈ $75.60K
+10.93%
2012-12-31 Skr633.30K
≈ $68.15K
--

About Simris Alg AB (publ)

ST:SIMRIS-B Sweden Biotechnology
Market Cap
$16.63 Million
Skr154.55 Million SEK
Market Cap Rank
#25649 Global
#529 in Sweden
Share Price
Skr0.11
Change (1 day)
-0.43%
52-Week Range
Skr0.04 - Skr0.17
All Time High
Skr14.17
About

Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammen… Read more